

The future of NGS is here

The Ion Torrent™ Genexus™ System

Provides a fast and automated end-to-end next-generation sequencing (NGS) solution, no matter your level of expertise.

Automating to reduce touchpoints

Touchpoint 1

- Nucleic acid (NA) extraction
- NA quantification
- Sequencing plate preparation
- Storage NA plate preparation

Touchpoint 2

- Library preparation
- Templating
- Sequencing
- Analysis

Research applications



Oncology



Inherited disease



Infectious disease**



Reproductive health**

Find out more at
thermofisher.com/ngs

* Formalin-fixed paraffin-embedded tissue
** Genexus Integrated Sequencer only


For Research Use Only. Not for use in diagnostic procedures. © 2021 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. **COL016024 0621**

Touchpoint 1



Genexus™ purification system

Touchpoint 2



Genexus™ integrated sequencer

1 report



Easy to analyze

Sample Cancer 1: Acute Myeloid Leukemia			
Relevant Acute Myeloid Leukemia Biomarkers			
Gene	Variant	Variant	Variant
ARL1	10: del	MLL2	11: del
ASX1	10: del	MLL3	11: del
CBP4	10: del	MLL4	11: del
CBP4	10: del	MLL5	11: del
FLT	13: 17q21.31	MLL6	11: del
FLT	13: 17q21.31	MLL7	11: del
FLT	13: 17q21.31	MLL8	11: del
FLT	13: 17q21.31	MLL9	11: del
FLT	13: 17q21.31	MLL10	11: del
FLT	13: 17q21.31	MLL11	11: del
FLT	13: 17q21.31	MLL12	11: del
FLT	13: 17q21.31	MLL13	11: del
FLT	13: 17q21.31	MLL14	11: del
FLT	13: 17q21.31	MLL15	11: del
FLT	13: 17q21.31	MLL16	11: del
FLT	13: 17q21.31	MLL17	11: del
FLT	13: 17q21.31	MLL18	11: del
FLT	13: 17q21.31	MLL19	11: del
FLT	13: 17q21.31	MLL20	11: del
FLT	13: 17q21.31	MLL21	11: del
FLT	13: 17q21.31	MLL22	11: del
FLT	13: 17q21.31	MLL23	11: del
FLT	13: 17q21.31	MLL24	11: del
FLT	13: 17q21.31	MLL25	11: del
FLT	13: 17q21.31	MLL26	11: del
FLT	13: 17q21.31	MLL27	11: del
FLT	13: 17q21.31	MLL28	11: del
FLT	13: 17q21.31	MLL29	11: del
FLT	13: 17q21.31	MLL30	11: del
FLT	13: 17q21.31	MLL31	11: del
FLT	13: 17q21.31	MLL32	11: del
FLT	13: 17q21.31	MLL33	11: del
FLT	13: 17q21.31	MLL34	11: del
FLT	13: 17q21.31	MLL35	11: del
FLT	13: 17q21.31	MLL36	11: del
FLT	13: 17q21.31	MLL37	11: del
FLT	13: 17q21.31	MLL38	11: del
FLT	13: 17q21.31	MLL39	11: del
FLT	13: 17q21.31	MLL40	11: del
FLT	13: 17q21.31	MLL41	11: del
FLT	13: 17q21.31	MLL42	11: del
FLT	13: 17q21.31	MLL43	11: del
FLT	13: 17q21.31	MLL44	11: del
FLT	13: 17q21.31	MLL45	11: del
FLT	13: 17q21.31	MLL46	11: del
FLT	13: 17q21.31	MLL47	11: del
FLT	13: 17q21.31	MLL48	11: del
FLT	13: 17q21.31	MLL49	11: del
FLT	13: 17q21.31	MLL50	11: del
FLT	13: 17q21.31	MLL51	11: del
FLT	13: 17q21.31	MLL52	11: del
FLT	13: 17q21.31	MLL53	11: del
FLT	13: 17q21.31	MLL54	11: del
FLT	13: 17q21.31	MLL55	11: del
FLT	13: 17q21.31	MLL56	11: del
FLT	13: 17q21.31	MLL57	11: del
FLT	13: 17q21.31	MLL58	11: del
FLT	13: 17q21.31	MLL59	11: del
FLT	13: 17q21.31	MLL60	11: del
FLT	13: 17q21.31	MLL61	11: del
FLT	13: 17q21.31	MLL62	11: del
FLT	13: 17q21.31	MLL63	11: del
FLT	13: 17q21.31	MLL64	11: del
FLT	13: 17q21.31	MLL65	11: del
FLT	13: 17q21.31	MLL66	11: del
FLT	13: 17q21.31	MLL67	11: del
FLT	13: 17q21.31	MLL68	11: del
FLT	13: 17q21.31	MLL69	11: del
FLT	13: 17q21.31	MLL70	11: del
FLT	13: 17q21.31	MLL71	11: del
FLT	13: 17q21.31	MLL72	11: del
FLT	13: 17q21.31	MLL73	11: del
FLT	13: 17q21.31	MLL74	11: del
FLT	13: 17q21.31	MLL75	11: del
FLT	13: 17q21.31	MLL76	11: del
FLT	13: 17q21.31	MLL77	11: del
FLT	13: 17q21.31	MLL78	11: del
FLT	13: 17q21.31	MLL79	11: del
FLT	13: 17q21.31	MLL80	11: del
FLT	13: 17q21.31	MLL81	11: del
FLT	13: 17q21.31	MLL82	11: del
FLT	13: 17q21.31	MLL83	11: del
FLT	13: 17q21.31	MLL84	11: del
FLT	13: 17q21.31	MLL85	11: del
FLT	13: 17q21.31	MLL86	11: del
FLT	13: 17q21.31	MLL87	11: del
FLT	13: 17q21.31	MLL88	11: del
FLT	13: 17q21.31	MLL89	11: del
FLT	13: 17q21.31	MLL90	11: del
FLT	13: 17q21.31	MLL91	11: del
FLT	13: 17q21.31	MLL92	11: del
FLT	13: 17q21.31	MLL93	11: del
FLT	13: 17q21.31	MLL94	11: del
FLT	13: 17q21.31	MLL95	11: del
FLT	13: 17q21.31	MLL96	11: del
FLT	13: 17q21.31	MLL97	11: del
FLT	13: 17q21.31	MLL98	11: del
FLT	13: 17q21.31	MLL99	11: del
FLT	13: 17q21.31	MLL100	11: del

Benefits

- 1** day results possible
- 2** user touchpoints
- 20** min hands-on time

Workflows

Use Oncomine™ Precision Assay workflows for a variety of sample types. Detect key biomarkers in half the time it takes with standard sequencing.

